CLRB · Cellectar Biosciences Inc. Common Stock
View on chartInsiders & Stakes
| Andrei Shustov Senior Vice President, Medical | ▲ Buy | Grant | 55,038 Shares held | 12/8/2023 | View profile |
| Darrell Shane Lea Chief Commercial Officer | ▲ Buy | Grant | 39,599 Shares held | 12/8/2023 | View profile |
| Douglas J. Swirsky CHIEF FINANCIAL OFFICER | ▲ Buy | Open Market | 25,000 Shares held | 9/14/2021 | View profile |
| Jarrod Longcor Chief Operating Officer | ▲ Buy | Open Market | 20,451 Shares held | 5/7/2026 | View profile |
| James Caruso V President and CEO | ▲ Buy | Open Market | 20,318 Shares held | 5/7/2026 | View profile |
| DRISCOLL FREDERICK W Director | ▲ Buy | Open Market | 19,417 Shares held | 9/3/2021 | View profile |
| Chad J. Kolean Chief Financial Officer | ▲ Buy | Open Market | 6,418 Shares held | 7/2/2025 | View profile |
| John Neis Director | ▼ Sell | Open Market | 10 Shares held | 12/12/2025 | View profile |
Transaction History
| Jarrod Longcor | ▲ Buy | Open Market | 8,680 | $25K | 5/7/2026 |
| James Caruso V | ▲ Buy | Open Market | 8,680 | $25K | 5/7/2026 |
| John Neis | ▼ Sell | Open Market | 198 | $732 | 12/12/2025 |
| James Caruso V | ▲ Buy | Open Market | 10,000 | $50K | 7/2/2025 |
| Jarrod Longcor | ▲ Buy | Open Market | 10,000 | $50K | 7/2/2025 |
| Chad J. Kolean | ▲ Buy | Open Market | 5,000 | $25K | 7/2/2025 |
| Jarrod Longcor | ▲ Buy | Open Market | 30,000 | $8K | 1/10/2025 |
| Darrell Shane Lea | ▲ Buy | Grant | 39,599 | $0 | 12/8/2023 |
| Chad J. Kolean | ▲ Buy | Grant | 42,554 | $0 | 12/8/2023 |
| Andrei Shustov | ▲ Buy | Grant | 47,856 | $0 | 12/8/2023 |
| Jarrod Longcor | ▲ Buy | Grant | 42,927 | $0 | 12/8/2023 |
| James Caruso V | ▲ Buy | Grant | 40,596 | $0 | 12/8/2023 |
| Douglas J. Swirsky | ▲ Buy | Open Market | 25,000 | $26K | 9/14/2021 |
| DRISCOLL FREDERICK W | ▲ Buy | Open Market | 19,417 | $20K | 9/3/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Cellectar to Present Iopofosine Data at Waldenström Workshop
Cellectar Biosciences plans to share efficacy data from the Phase 2 CLOVER trial at an upcoming international workshop. The presentation will focus on patients with Waldenström Macroglobulinemia who did not respond to BTK inhibitor therapy. This data point is relevant for observers tracking the progress of the company's lead candidate, iopofosine I 131.
Cellectar to Present Iopofosine Data at Waldenström Workshop. Cellectar Biosciences plans to share efficacy data from the Phase 2 CLOVER trial at an upcoming international workshop. The presentation will focus on patients with Waldenström Macroglobulinemia who did not respond to BTK inhibitor therapy. This data point is relevant for observers tracking the progress of the company's lead candidate, iopofosine I 131.